SCHEMBL4159072

SCHEMBL4159072

CC1CC(NC(=O)c2ccnc3[nH]c(-c4ccc(NCCN(C)C)cc4)nc23)CC(C)(C)C1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
RAD52 P43351 1/20 0.39
UHRF1 Q96T88 1/20 0.39
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
PBK Q96KB5 3/20 0.36
IDH1 O75874 1/20 0.35
ATM Q13315 1/20 0.34
GSK3B P49841 2/20 0.33
CDC7 O00311 1/20 0.33
CDK19 Q9BWU1 1/20 0.33
FASN P49327 1/20 0.32
ATAD2 Q6PL18 1/20 0.32
PARP1 P09874 1/20 0.32
TMEM97 Q5BJF2 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CFD P00746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161437 0.87 TDP1 (0.46) TDP1KDM4EALDH1A1HTTPBK
SCHEMBL4144891 0.85 RAD52 (0.42) RAD52UHRF1KDM4EALDH1A1PBK
SCHEMBL4153517 0.83 PBK (0.47) RAD52UHRF1PBKFASNATAD2
SCHEMBL13778203 0.82 ALDH1A1 (0.40) RAD52UHRF1KDM4EALDH1A1HTT
SCHEMBL13778206 0.82 ALDH1A1 (0.40) RAD52UHRF1KDM4EALDH1A1HTT
SCHEMBL13778200 0.82 GRK2 (0.38) RAD52UHRF1HTT
SCHEMBL4162695 0.81 ACVR1 (0.42) RAD52UHRF1PBK
SCHEMBL13778218 0.80 CNR1 (0.40) RAD52UHRF1PBKGSK3BCDC7
SCHEMBL4152708 0.80 RAD52 (0.39) RAD52UHRF1KDM4EPBKGSK3B
SCHEMBL4961738 0.80 RAD52 (0.43) RAD52UHRF1KDM4EGSK3BATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 TDP1 1051/4885RAD52 4618/4885UHRF1 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.